



⑫

EUROPEAN PATENT APPLICATION

⑳ Application number : **92307334.0**

⑤① Int. Cl.⁵ : **A61K 31/55, A61K 9/52,
A61K 9/54**

㉔ Date of filing : **11.08.92**

③① Priority : **12.08.91 GB 9117361**

④③ Date of publication of application :
17.02.93 Bulletin 93/07

⑧④ Designated Contracting States :
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**

⑦① Applicant : **Euroceltique SA**
122 Boulevard de la Petrusse
Luxembourg (LU)

⑦② Inventor : **Buxton, Ian Richard**
29 Youngman Avenue
Histon, Cambridge (GB)
Inventor : **Brown, Adrian**
2A High Street
Histon, Cambridge (GB)

Inventor : **Critchley, Helen**
17 Merton Road

Histon, Cambridge (GB)
Inventor : **Leslie, Stewart Thomas**
4 Babraham Road
Cambridge (GB)

Inventor : **Malkowska, Sandra Therese**
Antoinette

21 Broadway, Wilburton
Ely, Cambridge (GB)

Inventor : **Prater, Derek Allan**
28 Pearson Close

Milton, Cambridge (GB)
Inventor : **Miller, Ronald Brown**
Bruderholzallee 191
Basle 4059 (CH)

⑦④ Representative : **Lamb, John Baxter et al**
MARKS & CLERK 57-60 Lincoln's Inn Fields
London WC2A 3LS (GB)

⑤④ Compositions comprising diltiazem in sustained release form and hydrochlorothiazide in immediate release form.

⑤⑦ A solid oral dosage form comprising diltiazem (or a pharmaceutically acceptable salt thereof) in controlled release form and hydrochlorothiazide in normal release form. Preferably the controlled release component comprises a plurality of spheroids comprising diltiazem and a spheronising agent.

EP 0 527 638 A1

The present invention relates to a solid oral dosage form and to a process for its preparation. In particular it relates to a solid oral dosage form comprising a combination of diltiazem and hydrochlorothiazide for the treatment of hypertension.

Thiazide diuretics and in particular hydrochlorothiazide are widely used in antihypertensive therapy. Diltiazem is a calcium antagonist which has been shown to be useful in treating chronic heart disease such as angina and hypertension. The administration of diltiazem together with hydrochlorothiazide has been reported to produce significant additive effects in mild to moderate hypertension with twice-daily dosing (see Burris et al, JAMA, 263, (11), 1507-12, 1990).

It is an object of the present invention to provide a combined dosage form comprising diltiazem and hydrochlorothiazide suitable for once daily administration for the treatment of hypertension.

The present invention therefore provides a solid oral dosage form comprising diltiazem or a pharmaceutically acceptable salt thereof in controlled release form and hydrochlorothiazide in immediate release form.

Suitable pharmaceutically acceptable salts of diltiazem for use according to the present invention include pharmaceutically acceptable acid addition salts. The hydrochloride salt is particularly preferred.

The dosage forms according to the invention utilize diltiazem or its pharmaceutically acceptable salts in controlled release form. Known controlled release systems which may be used according to the invention include diffusion, erosion or osmosis controlled delivery system. Dissolution may be through a rate-controlling barrier or from a matrix system. Controlled release matrices containing swellable polymers which are capable of modifying the diffusion of the active ingredient across the barrier have also been described.

Erosion-controlled release systems deliver the active ingredient by slow dissolution or break up of the matrix. Suitable adjuvants such as hydrophilic gel-forming adjuvants or hydrophobic adjuvants may be added. In a hydrophilic matrix the release of the active ingredient will be controlled by the gel layer formed on contact with water or digestive fluids. Where hydrophobic adjuvants are employed, it is their erosion which controls the release rate.

In osmotic systems delivery of the active ingredient is controlled by the permeability of the membrane and the osmotic pressure generated by core matrix.

Alternatively release of the active ingredient may also be pH or time controlled.

Suitable materials for inclusion in a controlled release matrix include, for example

(a) Hydrophilic or hydrophobic polymers, such as gums, cellulose esters, cellulose ethers, protein derived materials, nylon, acrylic resins, polylactic acid, polyvinylchloride, starches, polyvinylpyrrolidones, cellulose acetate phthalate. Of these polymers, cellulose ethers especially substituted cellulose ethers such as alkylcelluloses and acrylic resins (for example methacrylates such as methacrylic acid copolymers) are preferred. The controlled release matrix may conveniently contain between 1% and 80% (by weight) of the hydrophilic or hydrophobic polymer.

(b) Digestible, long chain (C_8 - C_{50} , especially C_8 - C_{40}), substituted or unsubstituted hydrocarbons, such as fatty acids, hydrogenated vegetable oils such as Cutina (Trade Mark), fatty alcohols, glyceryl esters of fatty acids for example glyceryl monostearate mineral oils and waxes (such as beeswax, glycowax, castor wax or carnauba wax). Hydrocarbons having a melting point of between 25°C and 90°C are preferred. Of these long chain hydrocarbon materials, fatty (aliphatic) alcohols are preferred. The matrix may contain up to 60% (by weight) of at least one digestible, long chain hydrocarbon.

(c) Polyalkylene glycols. The matrix may contain up to 60% (by weight) of at least one polyalkylene glycol.

A suitable matrix comprises one or more cellulose ethers or acrylic resins, one or more C_{12} - C_{36} , preferably C_{14} - C_{22} , aliphatic alcohols and/or one or more hydrogenated vegetable oils.

A particularly suitable matrix comprises one or more alkylcelluloses, one or more C_{12} - C_{36} (preferably C_{14} - C_{22}) aliphatic alcohols and optionally one or more polyalkylene glycols.

The cellulose ether is preferably a substituted cellulose ether such as alkylcellulose and is preferably a substituted alkylcellulose such as ethylcellulose or a hydroxy (C_1 to C_6) alkyl cellulose, such as hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose phthalate and especially hydroxyethylcellulose. Preferably the matrix contains between 2% and 60%, especially between 3% and 50% (by wt) of the cellulose ether.

The acrylic resin is preferably a methacrylate such as methacrylic acid copolymer USNF Type A (Eudragit L, Trade Mark), Type B (Eudragit S, Trade Mark), Type C (Eudragit L 100-55, Trade Mark), Eudragit NE 30D, Eudragit E, Eudragit RL and Eudragit RS. Preferably the matrix contains between 2% and 60% by weight, particularly between 3% and 50% by weight of the acrylic resin.

The aliphatic alcohol may be, for example, lauryl alcohol, myristyl alcohol or stearyl alcohol but is preferably cetyl alcohol or cetostearyl alcohol. The amount of the aliphatic alcohol or hydrogenated vegetable oil will be determined by the precise rate of diltiazem release required and also on whether the polyalkylene glycol is pres-

ent or absent. In the absence of polyalkylene glycol, the matrix preferably contains between 8% and 40%, especially between 12% and 36% (by wt) of the aliphatic alcohol. When polyalkylene glycol is present in the oral dosage form, then the combined weight of the aliphatic alcohol and the polyalkylene glycol preferably constitutes between 2% and 40%, especially between 8% and 36% (by wt) of the matrix.

5 The polyalkylene glycol may be, for example, polypropylene glycol or, which is preferred, polyethylene glycol. The number average molecular weight of the at least one polyalkylene glycol is preferably between 200 and 15000 especially between 400 and 12000.

In addition to the above ingredients, the controlled release matrix may also contain suitable quantities of other materials, e.g. diluents, lubricants, binders, granulating aids, colorants, surfactants, anti-adherents, flavors and glidants that are conventional in the pharmaceutical art.

The diltiazem containing controlled release matrix of the invention can readily be prepared by dispersing the active ingredient in the controlled release system using conventional pharmaceutical techniques such as wet granulation, dry blending, dry granulation or coprecipitation.

15 In a preferred embodiment of the present invention the controlled release component comprises a plurality of beads, the beads comprising diltiazem or a pharmaceutically acceptable salt thereof and optionally a bead forming agent.

The term "bead" is conventional in the pharmaceutical art and means a spherical granule having a diameter of between 0.1mm and 2.5mm, especially between 0.5mm and 2mm. Included within this are inert cores composed of excipients which are coated with the active ingredient. Suitable inert excipients include sucrose, starch and microcrystalline celluloses. Preferably however the bead comprises spheroids comprising the active ingredient and optionally a spheronising agent.

The beads preferably contain between 40% and 98%, more preferably between 60% and 85%, especially between 70% and 85% by weight of diltiazem or its pharmaceutically acceptable salts.

25 In a particularly preferred embodiment of the invention the controlled release component comprises a plurality of spheroids comprising diltiazem or a pharmaceutically acceptable salt thereof and a spheronising agent.

The spheronising agent may suitably be any pharmaceutically acceptable material which may be spheronised together with the active ingredient to form spheroid cores. A preferred spheronising agent is microcrystalline cellulose. The microcrystalline cellulose employed may be, for example, Avicel PH 101 or Avicel PH 102 (Trade Marks, FMC Corporation). Conveniently the spheronising agent, when present, is present in an amount of from 1% to 60%, preferably from 15% to 40% by weight of the spheroid core.

In addition the spheroids may also contain a binder. Suitable binders which may be used are well known in the art and include hydrophilic polymers or hydrocolloids such as cellulose polymers, especially cellulose ethers, acrylic resins and gums. Water soluble hydroxy lower alkyl celluloses such as hydroxypropylcellulose are preferred. The binder is preferably present in an amount of from 1% to 40% by weight of the spheroid core.

35 Optionally the spheroid core may also contain other pharmaceutically acceptable excipients and diluents which facilitate spheronisation such as sugars (for example sucrose, dextrose, maltose or lactose) or sugar alcohols (for example mannitol, xylitol or sorbitol). Colourants may also be included in the spheroid core.

The spheroid cores are preferably film coated with a material which permits release of the diltiazem at a controlled rate in an aqueous medium. Suitable film coating materials include water insoluble waxes and polymers such as polymethacrylates (for example Eudragit polymers, Trade Mark) or preferably water insoluble celluloses particularly ethylcellulose. This film coat may also include water soluble polymers such as polyvinylpyrrolidone or preferably a water soluble cellulose such as hydroxypropylmethylcellulose and hydroxypropylcellulose. It will be appreciated that the ratio of water insoluble to water soluble material will depend on the release rate required and the solubility of the materials selected. The ratio of water soluble polymer to water insoluble polymer is preferably 1:20 to 1:2. The controlled release coating preferably includes one or more plasticisers conventional in the art such as diethylphthalate but particularly dibutyl sebacate; surfactants such as sorbitan trioleate, sorbitan monolaurate or preferably polysorbate 80 (Tween 80, Trade Mark) and tack-modifiers such as talc or preferably colloidal anhydrous silica.

50 The amount of plasticiser, when present, will depend on the particular plasticiser selected. In general, the plasticiser is present in an amount of from 1% to 25% by weight of the controlled release film coat. The surfactant, when present, is suitably present in an amount of from 1% to 25% by weight of the controlled release film coat. The tack-modifier, when present, is also suitably present in an amount of from 1% to 25% by weight of the controlled release film coat.

A preferred controlled release film coating comprises 50% to 95% ethylcellulose, 5% to 15% colloidal anhydrous silica, 5% to 15% dibutyl sebacate and 5% to 15% polysorbate 80 (Tween 80, Trade Mark).

The controlled release film coating layer can be formed on the surface of the diltiazem containing spheroid core using conventional coating methods, for example fluidised bed or pan coating. The coating materials may be applied as a solution or suspension. Suitable solvent systems include water, dichloromethane, ethanol, me-

thanol, isopropyl alcohol and acetone or a mixture thereof. The coating solution or suspension preferably contains from 2% to 60%, preferably from 2% to 20% by weight of coating materials.

The amount of controlled release coating material will depend on the desired release rate but is generally in the range of from 1% to 25%, preferably 2% to 8% by weight of the controlled release coated spheroid.

- 5 The diltiazem containing spheroids according to the invention may be prepared by
- (a) granulating a mixture comprising diltiazem or a pharmaceutically acceptable salt thereof, water and optionally a spheronising agent;
 - (b) extruding the granulated mixture to give an extrudate;
 - (c) spheronising the extrudate until spheroid cores are formed;
 - 10 (d) drying the spheroid cores and optionally
 - (e) film coating the spheroid cores

The solid oral dosage form according to the invention may be formulated as a bilayer tablet. In a preferred aspect however the solid oral dosage form comprises a core comprising diltiazem or a pharmaceutically acceptable salt thereof in controlled release form and an outer coating layer comprising hydrochlorothiazide for immediate release.

15 Conveniently the hydrochlorothiazide outer coating layer includes a water soluble hydrophilic polymer such as a cellulose ether (for example hydroxypropylcellulose or hydroxypropylmethyl cellulose), polyvinylpyrrolidone or xanthan gum. The ratio of polymer to hydrochlorothiazide is preferably from 10:1 to 1:10. Other coating excipients such as plasticisers, surfactants, tack modifiers, opacifiers and colourants may also be present. The hydrochlorothiazide and excipients are preferably present in the ratio of from 10:1 to 1:10.

The hydrochlorothiazide-containing outer coating layer can be formed on the diltiazem containing controlled release spheroid using conventional coating techniques such as fluidised bed coating or pan coating. Suitable solvents for the coating solution include water, ethanol, methanol, isopropanol or dichloromethane. It will be appreciated that the amount of coating material in the coating solution will depend on the ratio of drug to polymer and the viscosity of the solution. Conveniently the coating solution contains from 1% to 60% by weight of coating materials.

The weight ratio of diltiazem to hydrochlorothiazide in the dosage forms according to the invention typically ranges from about 30:1 to 4:1, preferably 20:1 to 6:1. The dosage form according to the present invention may suitably be administered once or twice daily. Conveniently for once daily administration the dosage form contains 120mg to 480mg of diltiazem or a pharmaceutically acceptable salt thereof, preferably diltiazem hydrochloride, and 6.25mg to 25mg hydrochlorothiazide. A preferred dosage form according to the invention for once daily administration contains 150mg diltiazem hydrochloride and 12.5mg hydrochlorothiazide.

For twice daily administration the dosage form conveniently contains 60mg to 240mg of diltiazem or a pharmaceutically acceptable salt thereof, preferably diltiazem hydrochloride and 3.125mg to 12.5mg hydrochlorothiazide. A preferred dosage form for twice daily administration contains 75mg diltiazem hydrochloride and 6.25mg hydrochlorothiazide.

Compositions according to the invention may be filled into capsules or sachets or compressed into tablets using conventional pharmaceutical techniques.

40 When the dosage form of the invention is administered orally the hydrochlorothiazide incorporated in the outer coating layer is rapidly released. The release and dissolution rate of the diltiazem in the core is controlled. When administered the dosage form provides rapid diuresis due to the fast release of the hydrochlorothiazide but also maintains an antihypertensive effect over a prolonged period of time because of the controlled release of diltiazem from the core.

45 In order that the invention may be well understood the following examples are given by way of illustration only.

Example 1

50 Capsule having the following formulation were prepared

55

Diltiazem spheroid coresMaterial

5		<u>mg</u>
	Diltiazem hydrochloride U.S.P.	150
	Microcrystalline cellulose E.P. (Avicel PH101)	37.5
10	Purified water E.P.	q.s.

		187.5

15

Controlled release film coat

20

Material

		<u>mg</u>
25	Diltiazem hydrochloride spheroid core	187.5
	Ethylcellulose N10 U.S.N.F.	9.225
	Colloidal anhydrous silica E.P. (Aerosil 130)	1.235
	Dibutyl sebacate U.S.N.F.	0.928
30	Polysorbate 80 E.P. (Tween 80)	0.989
	Dichloromethane BS 1994	q.s.
	Methanol B.P. 1973	q.s.
35		-----
		200

40

45

50

55

Hydrochlorothiazide film coat

<u>Material</u>	<u>mg</u>
Diltiazem hydrochloride controlled release film coated spheroids	200
Hydrochlorothiazide E.P.	12.5
Hydroxypropylmethylcellulose 5 cps E.P. (Methocel E5)	2.5
Purified water E.P.	q.s.

	215

The diltiazem and microcrystalline cellulose were blinded using a high shear mixer. The mixture was wet granulated, and extruded to give an extrudate which was spheronised and dried in a fluid bed drier. The spheroids were sieved to give a particle size of 0.85 to 1.7mm.

The controlled release film coating ingredient were dispersed in the dichloromethane/methanol solvent system and applied to the diltiazem spheroid cores in a fluid bed coater. The resulting film coated spheroids were sieved. The diltiazem containing controlled release spheroids were then film coated with the dispersion of hydrochlorothiazide and hydroxypropylmethylcellulose in a fluid bed coater.

The dissolution of the resulting product was measured by EP basket apparatus at 100rpm in pH 4.5 EP phosphate buffer. The results obtained are recorded below.

Hydrochlorothiazide Dissolution

10 minutes 100%

Diltiazem Dissolution

Time (hours)	Diltiazem controlled release/ hydrochlorothiazide spheroid (%)
1	8
2	20
3	32
4	41
5	50
6	57
8	66
10	73
12	77
15	83

The diltiazem release rate was unchanged by the application of the hydrochlorothiazide layer.

Example 2

Controlled release diltiazem cores having the following formulations were also prepared.

(i)		<u>Material</u>	<u>mg</u>
		Diltiazem hydrochloride Jap.P.	120.0
		Lactose E.P.	--
		Hydroxyethylcellulose E.P.	45.0
		Povidone K25 B.P.	10.0
		Purified water E.P.	N.D.
		Cetostearyl alcohol B.P.	30.0
		Purified talc E.P.	6.0
		Magnesium stearate E.P.	6.0

		Total Weight (mg)	217.0

		<u>Material</u>	<u>mg</u>
	(ii)	Diltiazem hydrochloride Jap.P.	120.0
		Microcrystalline cellulose E.P.	44.5
		Colloidal anhydrous silica E.P.	20.0
		Eudragit NE40D	80.0*
		Cetostearyl alcohol B.P.	52.5
		Magnesium stearate E.P.	3.0

		Total Weight (mg)	320.0

		* mg solids	

The diltiazem containing controlled release cores may be film coated with hydrochlorothiazide according to the procedure described in Example 1.

Claims

1. A solid oral dosage form comprising diltiazem or a pharmaceutically acceptable salt thereof in controlled release form and hydrochlorothiazide in immediate release form.
2. A dosage form according to claim 1 wherein the controlled release component comprises a plurality of beads comprising diltiazem or a pharmaceutically acceptable salt thereof.
3. A dosage form according to claim 2 wherein diltiazem or a pharmaceutically acceptable salt thereof is pres-

ent in an amount of from 40% to 98% by weight of the beads.

4. A dosage form according to any one of claims 2 or 3 wherein the controlled release component comprises a plurality of spheroids comprising diltiazem or a pharmaceutically acceptable salt thereof and a spher-
5 onising agent.
5. A dosage form according to claim 4 wherein the spheronising agent comprises microcrystalline cellulose.
6. A dosage form according to claim 4 or 5 wherein the spheronising agent is present in an amount of from
10 15% to 40% by weight of the spheroid core.
7. A dosage form according to any one of claims 4 to 6 wherein the spheroids are coated with a controlled release film coating material.
8. A dosage form according to claim 7 wherein the film coating material comprises a water insoluble polymer.
15
9. A dosage form according to any one of claim 8 wherein the film coating material comprises ethylcellulose.
10. A dosage form according to any one of claims 7 to 9 wherein the film coating material further comprises one or more plasticisers, surfactants and tack-modifiers.
- 20 11. A dosage form according to claim 10 wherein the film coating material comprises 50% to 95% ethylcellulose, 5% to 15% colloidal anhydrous silica, 5% to 15% dibutyl sebacate and 5% to 15% polysorbate 80.
12. A dosage form according to any one of claims 1 to 11 comprising a core comprising diltiazem or a pharmaceutically acceptable salt thereof in controlled release form and an outer coating layer comprising hydrochlorothiazide in immediate release form.
25
13. A dosage form according to any one of claims 1 to 12 wherein the weight ratio of diltiazem or its pharmaceutically acceptable salt to hydrochlorothiazide is in the range from 30:1 to 4:1.
- 30 14. A dosage form according to claim 13 comprising 150mg diltiazem hydrochloride and 12.5mg hydrochlorothiazide.
15. A capsule comprising a dosage form according to any one of claims 1 to 14.

35 **Claims for the following Contracting States : ES, GR**

1. A process for preparing a solid oral dosage form comprising combining diltiazem or a pharmaceutically acceptable salt thereof in controlled release form and hydrochlorothiazide in immediate release form.
- 40 2. A process according to claim 1 wherein the controlled release component comprises a plurality of beads comprising diltiazem or a pharmaceutically acceptable salt thereof.
3. A process according to claim 2 wherein diltiazem or a pharmaceutically acceptable salt thereof is present in an amount of from 40% to 98% by weight of the beads.
- 45 4. A process according to any one of claims 2 to 3 wherein the controlled release component comprises a plurality of spheroids comprising diltiazem or a pharmaceutically acceptable salt thereof and a spheronising agent.
- 50 5. A process according to claim 4 wherein the spheronising agent comprises microcrystalline cellulose.
6. A process according to claim 4 or 5 wherein the spheronising agent is present in an amount of from 15% to 40% by weight of the spheroid core.
7. A process according to any one of claims 4 to 6 wherein the spheroids are coated with a controlled release
55 film coating material.
8. A process according to claim 7 wherein the film coating material comprises a water insoluble polymer.

9. A process according to any one of claim 8 wherein the film coating material comprises ethylcellulose.
10. A process according to any one of claims 7 to 9 wherein the film coating material further comprises one or more plasticisers, surfactants and tack-modifiers.
- 5 11. A process according to claim 10 wherein the film coating material comprises 50% to 95% ethylcellulose, 5% to 15% colloidal anhydrous silica, 5% to 15% dibutyl sebacate and 5% to 15% polysorbate 80.
- 10 12. A process according to any one of claims 1 to 11 comprising coating a core comprising diltiazem or a pharmaceutically acceptable salt thereof in controlled release form with an outer coating layer comprising hydrochlorothiazide in immediate release form.
13. A process according to any one of claims 1 to 12 wherein the weight ratio of diltiazem or its pharmaceutically acceptable salt to hydrochlorothiazide is in the range from 30:1 to 4:1.
- 15 14. A process according to claim 13 comprising 150mg diltiazem hydrochloride and 12.5mg hydrochlorothiazide.

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 92 30 7334

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
A	EP-A-0 288 732 (SQUIBB) * Claims 1,9-12,14-15,17-28,32-34 * ---	1-15	A 61 K 31/55 A 61 K 9/52 A 61 K 9/54
A	EP-A-0 315 414 (TANABE SEIYAKU) * Claims 1-2,4-6,12-15; page 4, example 1; page 10, example 14 * -----	1-15	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			A 61 K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 22-10-1992	Examiner SCARPONI U.
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 01.92 (P0401)